Subject Index
acute myelitis, 17
acute optic neuritis, 77–80
afobazole, 274
alemtuzumab, 158
anandamide (AEA), 247–248
ANAVEX2-73, 278
anti-aquaporin-4 IgG (AQP4-IgG), 58
anti CD19 mAbs, 153–155
anti-CD20 mAbs, 142, 146–153
ocrelizumab, 148–151
ofatumumab, 152
rituximab, 147–148
ublituximab, 153
anti-CD20 monoc...